GSK reported positive survival data for Blenrep combined with bortezomib and dexamethasone in multiple myeloma DREAMM-7 trial, outperforming daratumumab combination therapy. GSK plans US relaunch in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback